Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far.

Thanuja M Y, Anupama C, Ranganath SH.

Adv Drug Deliv Rev. 2018 Jul;132:57-80. doi: 10.1016/j.addr.2018.06.012. Epub 2018 Jun 21. Review.

PMID:
29935987
2.

Controlled Inhibition of the Mesenchymal Stromal Cell Pro-inflammatory Secretome via Microparticle Engineering.

Ranganath SH, Tong Z, Levy O, Martyn K, Karp JM, Inamdar MS.

Stem Cell Reports. 2016 Jun 14;6(6):926-939. doi: 10.1016/j.stemcr.2016.05.003. Epub 2016 Jun 2.

3.

A Dual Tracer 18F-FCH/18F-FDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model.

Fu Y, Ong LC, Ranganath SH, Zheng L, Kee I, Zhan W, Yu S, Chow PK, Wang CH.

PLoS One. 2016 Feb 4;11(2):e0148123. doi: 10.1371/journal.pone.0148123. eCollection 2016.

4.

Focal cystic abdominal masses in pediatric patients.

Ranganath SH, Lee EY, Eisenberg RL.

AJR Am J Roentgenol. 2012 Jul;199(1):W1-16. doi: 10.2214/AJR.11.6642. Review. No abstract available.

PMID:
22733917
5.

Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.

Ranganath SH, Levy O, Inamdar MS, Karp JM.

Cell Stem Cell. 2012 Mar 2;10(3):244-58. doi: 10.1016/j.stem.2012.02.005. Review.

6.

Mediastinal masses in children.

Ranganath SH, Lee EY, Restrepo R, Eisenberg RL.

AJR Am J Roentgenol. 2012 Mar;198(3):W197-216. doi: 10.2214/AJR.11.7027. Review. No abstract available.

PMID:
22358017
7.

Current formulations and techniques of drug/gene delivery for targeted therapy and tissue engineering.

Wang CH, Ranganath SH.

Curr Pharm Des. 2010 Jul;16(21):2296-7. No abstract available.

PMID:
20618150
8.

The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice.

Ranganath SH, Fu Y, Arifin DY, Kee I, Zheng L, Lee HS, Chow PK, Wang CH.

Biomaterials. 2010 Jul;31(19):5199-207. doi: 10.1016/j.biomaterials.2010.03.002. Epub 2010 Mar 29.

PMID:
20350766
9.

Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy.

Ranganath SH, Kee I, Krantz WB, Chow PK, Wang CH.

Pharm Res. 2009 Sep;26(9):2101-14. doi: 10.1007/s11095-009-9922-2. Epub 2009 Jun 20.

PMID:
19543956
10.

Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme.

Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV, Wang CH.

Biomaterials. 2009 Jun;30(18):3189-96. doi: 10.1016/j.biomaterials.2009.02.030. Epub 2009 Mar 14.

PMID:
19285718
11.

Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma.

Ranganath SH, Wang CH.

Biomaterials. 2008 Jul;29(20):2996-3003. doi: 10.1016/j.biomaterials.2008.04.002. Epub 2008 Apr 18.

PMID:
18423584
12.

Immune system dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein kinase.

Hurov JB, Stappenbeck TS, Zmasek CM, White LS, Ranganath SH, Russell JH, Chan AC, Murphy KM, Piwnica-Worms H.

Mol Cell Biol. 2001 May;21(9):3206-19.

13.

Molecular mechanisms in T helper phenotype development.

Farrar JD, Ranganath SH, Murphy KM.

Springer Semin Immunopathol. 1999;21(3):211-30. Review. No abstract available.

PMID:
10666770
14.

Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism.

Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC, Murphy KM.

Immunity. 1998 Nov;9(5):745-55.

Supplemental Content

Loading ...
Support Center